Table 3.

Mean and SD of neuropsychological raw values at baseline and follow-up.

Cognitive domain	Cognitive measure	Mean baseline (SD)	Range baseline	Mean follow-up (SD)	Range follow-up	p-Value
Verbal learning	RAVLT 1–5	57.10 (9.22)	40–72	58.29 (11.29)	30–75	0.069
Verbal memory	RAVLT 6	11.70 (3.11)	5–15	11.33 (3.81)	1–15	0.917
	RAVLT 7	11.60 (3.60)	2–15	12.33 (3.00)	6–15	0.229
	RAVLT recog.	14.40 (1.05)	11–15	14.33 (1.49)	9–15	0.364
Attentional span	Digit span forwards	7.48 (2.56)	2–12	7.52 (2.04)	3–12	0.930
Processing speed	RCFT time	240.38 (105.34)	71–455	168.95 (63.89)	70–280	0.002
	SDMT	44.20 (11.15)	24–59	48.52 (10.05)	25–63	<0.001
	TMT-A	27.95 (9.88)	13–44	27.80 (9.25)	16–50	0.662
Visuoconstruction	RCFT copy	31.62 (4.23)	18–36	30.43 (3.18)	21.5–33	0.071
Visual memory	RCFT recall	20.12 (6.67)	8.5–31	21.69 (6.38)	7–34.5	0.590
Executive functions	Digit span BW	6.95 (2.33)	4–11	7.48 (3.49)	3–19	0.977
	Trail Making Test B (TMT-B)	66.85 (23.44)	34–120	64.69 (19.00)	29–107	0.641
	Phon. fluency	13.81 (5.23)	7–29	13.90 (5.22)	3–26	0.610
	Sem. fluency	22.95 (5.58)	10–37	24.14 (6.65)	11–40	0.256

Wilcoxon signed-rank tests comparing the baseline cognitive function with cognitive function at follow-up in N = 21 RRMS patients with Alemtuzumab treatment. Cognitive tests in bold show a significant performance increase at level α = 0.036 (Bonferroni correction for number of comparisons).

RAVLT, Rey auditory verbal learning test; digit span: digit span forward; RCFT, Rey Complex Figure Test; TMT-A, Trail Making Test part A; SDMT, Symbol Digit Modalities Test (written); Digit Span BW, Digit span backwards; TMT-B, Trail Making Test part B; Phon. Fluency, Phonematic verbal fluency with letter S (1 min.); Sem. fluency, Semantic verbal fluency with animals (1 min).